Table 1.
Demographics and baseline characteristics, including biomarkers
| Control group (n=317) | Bevacizumab group (n=319) | |
|---|---|---|
| Sex | ||
| Men | 170 (54%) | 171 (54%) |
| Women | 147 (46%) | 148 (46%) |
| Age, years | 65·0 (10·3) | 64·8 (104) |
| Race | ||
| White | 257 (81%) | 264 (83%) |
| Black | 33 (10%) | 21 (7%) |
| Asian/Pacific islander | 18 (6%) | 23 (7%) |
| Hispanic | 8 (3%) | 10 (3%) |
| American Indian/Alaskan native | 1 (<1%) | 0 |
| Other | 0 | 1 (<1%) |
| Smoking history | ||
| Never | 33 (10%) | 34 (11%) |
| Previous | 212 (67%) | 237 (74%) |
| Current | 72 (23%) | 48 (15%) |
| ECOG performance status score | ||
| 0 | 121/317 (38%) | 129/318 (41%) |
| 1 | 176/317 (56%) | 166/318 (52%) |
| 2 | 20/317 (6%) | 23/318 (7%) |
| Time since initial diagnosis | ||
| <6 months | 78/312 (25%) | 77/313 (25%) |
| 6–12 months | 122/312 (39%) | 120/313 (38%) |
| >12 months | 112/312 (36%) | 116/313 (37%) |
| Histology | ||
| Large-cell carcinoma | 25 (8%) | 23 (7%) |
| Adenocarcinoma | 235 (74%) | 242 (76%) |
| Squamous | 17 (5%) | 11 (3%) |
| Other* | 40 (13%) | 43 (13%) |
| Patients with treated brain metastases | 30 (9%) | 38 (12%) |
| EGFR status | ||
| FISH positive | 43/102 (42%) | 33/102 (32%) |
| FISH negative | 59/102 (58%) | 69/102 (68%) |
| IHC positive | 119/161 (74%) | 135/184 (73%) |
| IHC negative | 42/161 (26%) | 49/184 (27%) |
| EGFR mutant | 18/170 (11%) | 12/185 (6%) |
| EGFR wild-type | 152/170 (89%) | 173/185 (94%) |
| Kras mutation status | ||
| Mutant | 38/178 (21%) | 48/190 (25%) |
| Wild-type | 140/178 (79%) | 142/190 (75%) |
Data are n (%), mean (SD), or n/n with assessable tissue and test results (%). ECOG=Eastern Cooperative Oncology Group. EGFR=epidermal growth factor receptor. FISH=fluorescence in-situ hybridisation. IHC=immunohistochemistry.
*
Includes bronchoalveolar carcinoma and tumours defined as not otherwise specified or other.